Skip to main content
OpenTrials
Completed

NCT Number: NCT05076435

Restrictive Fluid Administration vs. Standard of Care in Emergency Department Sepsis Patients

This is an investigator-initiated, multicenter, randomized, parallel-group, open-labeled, feasibility trial investigating volumes of fluid within 24 hours in 124 patients with sepsis allocated to two different IV fluid regimens enrolled at three emergency departments in Central Region Denmark. The primary outcome is total intravenous, crystalloid fluid volume within 24 hours and key secondary outcomes include protocol violations, total fluids (intravenous and oral) within 24 hours, SAEs/SUSARs, and inhospital-, 30- and 90-day mortality.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Department of Emergency Medicine, Aarhus University Hospital, Aarhus, Central Jutland, Denmark

Loading trial locations.

About this study

BACKGROUND:

Sepsis is common in emergency department (ED) patients. Traditionally, intravenous (IV) fluids are used to optimise the circulation, and the use of higher volumes is recommended by international guidelines, but there are no recommendations for sepsis without hypotension or shock. Studies in septic shock seem to favour fluid restriction. Whether this is true in sepsis without hypotension/shock is unknown.

OBJECTIVES:

The aim of the REFACED Sepsis trial is to test if an IV fluid restrictive protocol in ED patients with sepsis is feasible, i.e., if the protocol decreases the IV fluid volumes administered.

DESIGN:

REFACED Sepsis is a multicenter, randomized, parallel-group, open-labeled, feasibility trial

POPULATION:

ED patients with sepsis expected to be admitted for ≥ 24 hours

EXPERIMENTAL INTERVENTION:

In the IV fluid restriction group no IV fluids should be given unless one of the below mentioned occurs;

A fluid bolus of 250 ml isotonic crystalloid may be given within 15 minutes if one of the following occurs (hypoperfusion criteria):

  • Lactate concentration ≥ 4 mmol/l (arterial or venous blood gas/blood sample)
  • Hypotension (systolic BP < 90 mmHg)
  • Mottling beyond edge of kneecap (i.e., Mottling score >2)53
  • Severe oliguria, i.e., diuresis < 0.1 ml/kg/h, during the first 4 hours of admission

All patients will be ensured min. 1 L of oral/intravenous fluids in 24 hours and electrolytes can be corrected.

CONTROL INTERVENTION:

In the usual care group there will be no upper limit for the use of IV fluids.

OUTCOMES:

The primary outcome is 24-hour intravenous crystalloid fluid administration. Key secondary outcomes are: Feasibility measures: Number of patients with major protocol violations, Number of patients screened vs included, Time from admission to inclusion, Number of patients lost to follow up in terms of 24-hour fluids, Accumulated serious adverse reactions and events (SAEs + Suspected Unexpected Serious Adverse Reaction (SUSARs)) within 48 hours in-hospital, Total fluids (oral and intravenous) at 24 hours,

TRIAL-SIZE:

124 patients will be randomized to restrictive fluid administration or usual care within 24 hours of randomization

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All of the below must be fulfilled:

  • Unplanned emergency department admission
  • Age ≥ 18 years
  • Sepsis defined as
  • suspected infection by the treating clinician AND
  • blood cultures drawn AND
  • IV antibiotics administered or planned AND
  • An infection related increase of SOFA*-score ≥ 2 from baseline
  • Expected hospital stay > 24 hours as deemed by treating clinician
  • Sequential Organ Failure Assessment (SOFA) Score

Further more the patient must fulfill criteria for enrollment in an acute study according to Danish law

Exclusion criteria

We will exclude patients fulfilling any of following exclusion criteria:

  • ≥ 500 ml of fluids given prior to randomization
  • Invasively ventilated or vasopressors initiated at the time of screening
  • Known or suspected severe bleeding judged by the treating clinician
  • Known or suspected pregnancy (women aged <45 years will have a pregnancy test performed before enrollment)
  • Prior enrollment in the trial
  • Patients, who the clinician expect not to survive the next 24-hours

Treatment and study plan

Isotonic crystalloids

Drug

Types of fluids in both intervention groups:

  • Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency
  • Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used.
  • Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy.

Primary outcomes

  1. 24-hour crystalloid iv. fluids

    Time frame: 24 hours from randomization

    total amount of all administered intravenous, crystalloid fluids within 24 hours of randomization

Secondary outcomes

  1. Protocol violations

    Time frame: 24 hours from randomization

    Feasibility measure: Number of patients with major protocol violations

  2. Screened-vs.-randomized-ratio

    Time frame: Through study completion, an average of 1 year

    Feasibility measure: Number of patients screened vs included

  3. Time to inclusion

    Time frame: Through study completion, an average of 1 year

    Feasibility measure: Time from admission to inclusion/randomization (hours)

  4. Lost-to-follow-up-rate

    Time frame: 24 hours from randomization

    Feasibility measure: Number of patients lost to follow up in terms of 24-hour fluids

  5. Accumulated serious adverse reactions (SARs + SUSARs)

    Time frame: 7 days from randomization

    Feasibility measure: Accumulated serious adverse reactions and events (SAEs + SARs+ SUSARs) within 7 days in-hospital

  6. Total 24-hour fluids

    Time frame: 24 hours from randomization

    Total fluids (oral and intravenous) at 24 hours

  7. Mortality

    Time frame: Total of 90-days

    In-hospital, 30- and 90-days mortality

Sponsors and collaborators

Lead sponsor

Marie Kristine Jessen, MD

Other

Collaborators

  • Aarhus University Hospital
  • Randers Regional Hospital
  • University of Aarhus
  • Viborg Regional Hospital

Registry information

Official study title

Restrictive Fluid Administration vs. Standard of Care in Emergency Department Sepsis Patients - a Multicenter, Randomized Clinical Feasibility Trial (REFACED Sepsis)

Acronym: REFACED Sepsis

Important dates

Study start
2021
Primary completion
2021
Study completion
2022
First posted
Oct 13, 2021
Registry last updated
Mar 25, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.